Annals of Oncology

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Annals of Oncology
Apr 23, 2025, 20:54 | Blog
ESMO Calls for Abstract Submissions Ahead of May 13 Deadline
ESMO - European Society for Medical Oncology shared on LinkedIn: "Breakthroughs start here! If you…
Apr 13, 2025, 06:03 | Blog
Results from the multicenter PALMARES-2 study
Flavia Jacobs, Medical Research Fellow at Institute Jules Bordet, recently shared on LinkedIn: "Don’t miss…
Apr 8, 2025, 18:01 | Blog
ESMO recommendations released to provide a roadmap to facilitate the implementation of MTBs in clinical practice
ESMO (European Society for Medical Oncology) shared a post on LinkedIn: "New ESMO recommendations released…
Apr 8, 2025, 07:38 | Blog
Giuseppe Curigliano: ESMO Recommendations on Molecular Tumour Boards in Clinical Practice
Giuseppe Curigliano, Member of the Editorial Board for OncoDaily and President Elect of ESMO, posted…
Apr 6, 2025, 14:30 | Blog
Gustavo Viani: HDR vs LDR Boost in Prostate Cancer
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared an article by…
Apr 6, 2025, 13:37 | Insight
Erick Saldanha: The role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade in solid tumours
Erick Saldanha, Medical Oncologist and Postdoctoral Clinical Fellow at Princess Margaret Cancer Centre, shared a…
Feb 26, 2025, 10:50 | Insight
Jarushka Naidoo: Mucinous lung adenocarcinomas - clinical features and outcomes
Jarushka Naidoo, Full Professor and Consultant Medical Oncologist at Royal College of Surgeons in Ireland,…
Feb 16, 2025, 04:58 | Blog
Tom Powles: TROPICS4 - sacituzimab govitecan vs chemo in pretreated urothelial carcinoma
Tom Powles, Professor at the University of London, shared a post on X: "TROPICS4 sacituzimab…
Feb 10, 2025, 09:58 | Science
Brigatinib vs alectinib in crizotinib-refractory advanced ALK+ NSCLC by James Chih-Hsin Yang et al.
In November 2022, a paper by James Chih-Hsin Yang et al. was published in Annals…
Jan 29, 2025, 18:10 | Blog
January highlights from the ESMO portfolio - Elsevier Oncology
Elsevier Oncology shared a post on LinkedIn: "See this month’s highlights from the ESMO -…
Jan 25, 2025, 12:41 | Insight
Elvina Almuradova: Targeting c-MET overexpression is reshaping EGFR-mutant NSCLC treatment
Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on X: “Breaking News from…
Jan 20, 2025, 16:03 | Insight
Navneet Singh: Ensuring global access to the 3 'A's of treatment
Navneet Singh, Thoracic Medical Oncologist at the Postgraduate Institute of Medical Education and Research, shared…
Jan 16, 2025, 08:42 | Insight
Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X…
Jan 13, 2025, 11:50 | Oncologist Near Me
Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer
Welcome to OncoDaily’s special section “Oncologist Near Me”, where we introduce prominent oncologists from around…
Jan 10, 2025, 17:16 | Insight
Fabrice André has been elected as the President of the ESMO for the term 2025-2026
As the Head of the Research Division at Gustave Roussy Cancer Campus in France, Professor…
Dec 24, 2024, 07:42 | Science
Serena Di Cosimo: The prognostic value of residual tumor biology during neoadjuvant treatment in patients with HER2+ breast cancer
Serena Di Cosimo, Medical Director at IRCCS Foundation National Cancer Institute, Milan, shared a recent…
Dec 12, 2024, 16:27 | Insight
Vivek Subbiah: Optimizing Tomorrow’s Drug Development with Project Optimus
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared…
Dec 12, 2024, 16:15 | Blog
In 2022, Annals Of Oncology transitioned to an online-only format - ESMO
ESMO - European Society for Medical Oncology shared a post on LinkedIn: “In 2022, Annals…
Dec 12, 2024, 16:06 | Insight
Isabelle Ray-Coquard: New publication from ENGOTov25 Paola-1 study
Isabelle Ray-Coquard, Medical Oncologist at Léon Bérard Center, shared a post on LinkedIn, about a…
Dec 12, 2024, 13:21 | Insight
Nicole Charbel: Examining the effect of spirituality on the quality of life amongst patients with Cancer
Nicole Charbel, Postdoctoral Research Fellow in the Hematology/Oncology Department at American University of Beirut, shared…
Dec 11, 2024, 09:53 | Insight
Thomas Powles was appointed Editor-in-Chief of Annals of Oncology
Thomas Powles was appointed  the Editor-in-Chief of Annals of Oncology in early 2024. Thomas Powles,…
Dec 10, 2024, 13:53 | Blog
97P Neoadjuvant D+GemCis vs gemcis alone for localized biliary tract cancer
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute and Post DM…
Dec 8, 2024, 06:05 | Insight
Alessandro Di Federico: Lung adenocarcinomas with Mucinos Histology
Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a…
Dec 8, 2024, 04:47 | Insight
Exciting developments in the management of unresectable stage III EGFR NSCLC
Aakash Desai, Assistant Professor and Associate Director at UAB O'Neal Comprehensive Cancer Center, shared an…
Dec 5, 2024, 15:37 | Insight
Two top-cited 2023 papers on Annals Of Oncology - ESMO
ESMO shared on LinkedIn: "As Annals Of Oncology 35th Anniversary is commemorated, here are two…
Dec 5, 2024, 09:37 | Blog
Tremelimumab and durvalumab for MSI-H gastric cancer
Yakup Ergün, Medical Oncologist at Bower Hospital, shared a paper by Raimondi et al. on…
Dec 3, 2024, 18:00 | Blog
Annals of Oncology Impact factor surpassed 10 in 2017 - ESMO
ESMO - European Society for Medical Oncology posted the following on LinkedIn: “Milestones Monday Annals…
Dec 3, 2024, 17:22 | Insight
Actions to Boost Lung Cancer Research and Innovation
Giannis Mountzios, Consultant Medical Oncologist of the 2nd Oncology Department and Clinical Trials Unit at…
Dec 3, 2024, 17:07 | Insight
The Efficacy and Safety of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer - Annals of Oncology
Annals of Oncology shared a recent article by A. Alvarez Secord on X: "New article…
Dec 3, 2024, 14:29 | Blog
ESMO - In 2014, Jean-Charles Soria became the youngest Editor-in-Chief in the journal's history
ESMO shared on LinkedIn: "Milestones Monday: In 2014, Jean-Charles Soria became the youngest Editor-in-Chief in the…
Dec 1, 2024, 21:13 | Blog
Jean-Charles Soria's discussion about Annals Of Oncology's evolution and its impact on oncology - ESMO
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "To mark the…
Nov 21, 2024, 16:28 | Insight
2023 top-cited paper to mark 35 years of Annals of Oncology
ESMO - Eur. Oncology shared an article by D.J. McGrail on X: " To mark…
Nov 15, 2024, 15:56 | Blog
Mark 35 years of Annals of Oncology with ESMO
ESMO shared on LinkedIn: "ESMO invites you to mark 35 years of Annals of Oncology. Over…
Nov 13, 2024, 23:26 | Insight
Efficacy of subsequent therapies in advanced ovarian cancer
Annals of Oncology shared a post on X: “New article in press: Efficacy of subsequent…
Nov 10, 2024, 02:00 | Insight
Nelson Dusetti: The applicability of our signatures in predicting treatment sensitivity and resistance in PDAC patients
Nelson Dusetti, Scientific Director of the company Predicting Med(CSO) and Chair of TRANSLATE-IT CRCM, shared an…
Oct 31, 2024, 14:59 | Insight
pCR rates for patients with HR+/HER2 breast cancer - Annals of Oncology
Annals of Oncology shared a post on X about a recent paper by L.A. Huppert et…
Oct 31, 2024, 14:58 | Insight
Hope Rugo: Important work on HR+ disease by Laura Huppert
Hope Rugo, Professor of medicine at the University of California San Francisco, shared an article…
Oct 26, 2024, 10:49 | Blog
AMG193 shows antitumor activity in MTAP-deleted solid tumors
Ben Westphalen, Chair of the Translational Research and Precision Medicine Working Group, shared a recent…
Oct 23, 2024, 10:40 | Insight
Paolo Tarantino: Final iDFS results from NATALEE published in Annals of Oncology
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared…
Oct 20, 2024, 19:52 | Blog
Stephen V Liu: Case report in Annals of Oncology of patients with NUT carcinoma responding to lurbinectedin
Stephen V Liu shared a post on X, about recent case report published in Annals…
Oct 17, 2024, 16:48 | Insight
Markus Eckstein: A huge paper corroborating results that we published in European Urology for urothelial cancer
Markus Eckstein, Senior Physician/Pathologist and Clinician Scientist at the University Hospital Erlangen, shared a post…
Oct 15, 2024, 12:53 | Insight
Marco Tagliamento: What might be platinum backbone in immunotherapy-containing regimens for lung cancer
Marco Tagliamento, Assistant Professor at University of Genoa, shared a post on X: "In Annals…
Oct 13, 2024, 10:59 | Insight
Alessandro Di Federico: Honored to have our work highlighted in this months issue of Annals of Oncology
Alessandro Di Federico shared a post by Annals of Oncology on X, adding: "Honored to have…
Sep 23, 2024, 19:52 | Blog
Vivek Subbiah: The pre-proof version of the editorial commentary on Optimizing Tomorrow’s Drug Development with Project Optimus
Vivek Subbiah shared his recent article on LinkedIn: "Pleased to share the pre-proof version of…
Sep 16, 2024, 13:24 | Dialogues
OncoDaily: France Bureau // vol.1
Tatev-Sargsyan Lefort presents the latest oncology news roundup from the past week, with a focus…
Sep 10, 2024, 10:38 | Blog
Vivek Subbiah: Precision Dosing IS Precision Oncology
Vivek Subbiah shared a post on X: “Pleased to share the pre-proof version of the…
Sep 7, 2024, 10:06 | Blog
Is adjuvant ribociclib ready for prime time?
Sarah Sammons shared a post by Paolo Tarantino, on X: "The number needed to treat (NNT) to…
Sep 1, 2024, 08:12 | Insight
Enhancing post - operative treatment for pancreatic ductal adenocarcinoma through AI
Nelson Dusetti posted on X: “We are very grateful to Davide Melisi for the thoughtful…
Aug 31, 2024, 14:15 | Insight
Tumour-agnostic authorised indications by FDA and EMA
Elisa Agostinetto shared a post on X about a recent paper by Benedikt Westphalen et…
Aug 30, 2024, 15:30 | Insight
Davide Melisi: Predicting sensitivity to chemotherapeutic treatments in pancreatic cancer with AI
Davide Melisi, Associate Professor of Medical Oncology at University of Verona, shared a post on…
Aug 29, 2024, 17:06 | Insight
ESMO announces Tumour-Agnostic Classifier and Screener in Annals of Oncology
ESMO - European Society for Medical Oncology shared a post on LinkedIn: "ESMO is pleased…
Aug 27, 2024, 23:09 | Blog
Juliana Beal: Our ETAC-S paper was published in Annals of Oncology
Juliana Beal, Medical oncologist at Hospital Israelita Albert Einstein, shared on X: "So I just got…
Aug 17, 2024, 16:35 | Career
Matti Aapro is running for the UICC Board of Directors
It is our honor to announce that the Chair of the Editorial Board of the…
Aug 9, 2024, 17:49 | Insight
Soraia Lobo-Martins: Tumour Heterogeneity in Molecular Imaging for Breast Cancer
Soraia Lobo-Martins, Medical Research Fellow at Jules Bordet Institute, shared on X: "Excited to share…
Jul 27, 2024, 07:00 | Insight
Characterisation of acquired mechanisms of resistance to PARP inhibitors
Annals of Oncology shared a post on X: "In Annals of Oncology, a Letter to…
Jul 25, 2024, 13:49 | Insight
Luca Arecco: Impact of hormone receptor status and tumor subtypes on prognosis of breast cancer in young BRCA carriers
Luca Arecco, Medical Oncology Resident at IRCCS Ospedale Policlinico San Martino, on X: "Published in…
Jul 25, 2024, 00:35 | Insight
Rodrigo Sánchez-Bayona: Our editorial on CDK4/6i impacted the OS in first-line for HR+/HER2- advanced breast cancer
Rodrigo Sánchez-Bayona, Medical Oncologist specialising in breast and gynecological cancers at 12 de Octubre University Hospital,…
Jul 23, 2024, 11:27 | Insight
Luca Malorni: Our editorial discussing the results of the SERENA-1 trial
Luca Malorni, Director of the Translational Research Unit at AUSL Toscana Centre at Hospital of…
Jul 19, 2024, 14:02 | Insight
The results of the IMpassion132 trial
Elisa Agostinetto shared on X a paper by Rebecca Dent et al. titled "IMpassion132 double-blind…
Jul 12, 2024, 17:41 | Blog
Raffaella Casolino: Insights from WHA77 and WHO Global Status Report on Cancer 2025
Raffaella Casolino, Technical Officer at World Health Organization and Honorary Clinical Senior Lecturer at University…
Jul 11, 2024, 04:05 | Blog
Annals of Oncology - Long-term results of the UNICANCER-PRODIGE 23 trial
Annals of Oncology shared on X: "New article in press: Total neoadjuvant therapy with mFOLFIRINOX versus…
Jul 9, 2024, 06:03 | Insight
Translational Breast Cancer Research Consortium Trial 022 - Annals of Oncology
Annals of Oncology made the following post on X: "New article in press: Neratinib and Ado-Trastuzumab-Emtansine…
Jul 6, 2024, 13:29 | Blog
ESMO - immune cell-related biomarkers in metastatic HNSCC
ESMO shared on LinkedIn: "Latest podcast. Annals of Oncology Editor in Chief Tom Powles talks to…
Jul 4, 2024, 12:28 | Blog
Emir Sokolović: The largest study focusing on young women with breast cancer carrying germline BRCA PV
Emir Sokolović, Medical Oncology Resident at Clinical center University of Sarajevo, shared on LinkedIn: "Our…
Jul 3, 2024, 18:13 | Blog
Alessandro Di Federico: Intrapatient variation in PD-L1 and TMB
Alessandro Di Federico, Medical Oncologist and PhD student at University of Bologna, shared a post on…
Jul 2, 2024, 12:04 | Career
Luca Arecco was awarded the ASCO Conquer Cancer Merit Award
Matteo Lambertini shared a post by San Martino Hospital, Genova on X, adding: “Congrats Luca Arecco…
Jul 1, 2024, 15:01 | Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jul 1, 2024, 13:46 | Blog
The July issue of Annals of Oncology
Annals of Oncology shared a post on LinkedIn: “New online - the July issue of…
Jun 28, 2024, 11:08 | Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
Jun 23, 2024, 14:32 | Blog
Impact of Hormone Receptor Status and Tumor Subtypes of Breast Cancer in Young BRCA Carriers
Matteo Lambertini shared a post by Annals of Oncology, on X: "Presented at ASCO24 by Luca Arecco and…
Jun 22, 2024, 14:12 | Insight
New Paper Alert! Novel Tool Predicts Chemotherapy Response in Pancreatic Cancer Using AI-assisted Transcriptomic Signatures
Novel Tool Predicts Chemotherapy Response in Pancreatic Cancer Using AI-assisted Transcriptomic Signatures Authors: Nicolas Fraunhoffer,…
Jun 19, 2024, 12:19 | Blog
Oncology Advance - See this month’s highlights from the ESMO portfolio
Oncology Advance shared a post on X: "See this month’s highlights from the ESMO portfolio. Featured…
Jun 15, 2024, 07:36 | Blog
Tom Powles and Giorgio Bogani Discuss the Recently Published Study on Advanced or Recurrent Endometrical Cancer
The European Society for Medical Oncology (ESMO) posted on LinkedIn: “Latest podcast Annals of Oncology Editor-in-Chief…
Jun 12, 2024, 01:33 | Insight
Upfront resection versus no resection of the primary tumor in patients with synchronous mCRC - Julius Center Research Program Cancer
Julius Center Research Program Cancer shared a post on LinkedIn:           …
Jun 10, 2024, 11:27 | Insight
Arndt Vogel on a paper by D.E.W. van der Kruijssen et al.
Arndt Vogel shared a post on X: "Upfront resection vs no resection of the primary…
Jun 10, 2024, 10:31 | Opinion
Armando Orlandi: To explain the unexplainable in MONARCH 3
Armando Orlandi, Medical Oncologist at Agostino Gemelli University Policlinic, made the following post on X:…
Jun 7, 2024, 09:11 | Insight
Erika Hamilton: Happy to share the publication in Annals of Oncology
Erika Hamilton shared a post on X: “Happy to share the publication in Annals of…
May 24, 2024, 13:24 | Insight
Erman Akkus Summarizes 5-year Results of CheckMate 040
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: “Nivolumab plus ipilimumab…
May 24, 2024, 11:17 | Insight
Piotr Wysocki: Patients with hypermutated colorectal cancer (POLE/D1pd) derive profound benefit from immunotherapy
Piotr Wysocki recently posted on LinkedIn: "Ambrosini N et al. published online (Annals of Oncology) the…
May 14, 2024, 14:59 | Blog
Annals of Oncology March 2024 issue article of the month
Annals of Oncology shared a post by Annals of Oncology on X/Twitter, adding: ''The article…
May 13, 2024, 07:59 | Blog
Erika Hamilton: Check out our new practice LinkedIn page
Erika Hamilton shared a post by SCRI Oncology Partners on LinkedIn, adding: ''Check out our new practice…
May 12, 2024, 14:34 | Societies
Tom Powles talks to Amanda Psyrri about immune cell-related biomarkers in HNSCC - ESMO
ESMO - European Society for Medical Oncology shared on LinkedIn: “Latest podcast Annals of Oncology…
May 9, 2024, 11:35 | Insight
Vivek Subbiah: SERENA-1 monotherapy results in Annals of Oncology
Quoting Vivek Subbiah on X: . "A Phase 1 dose escalation and expansion trial of…
Apr 23, 2024, 20:12 | Blog
Antonio Passaro: An honor to have been a part of this significant manuscript, just out in Annals of Oncology driving forward the clinical development of ADCs
Antonio Passaro, Medical Director with Highly Specialized Position at IEO European Institute of Oncology, shared on…
Apr 23, 2024, 11:38 | Insight
Antonio Passaro: ETOP IBCSG Partners Foundation's position statement on antibody-drug conjugates (ADC) in lung and breast cancer
Antonio Passaro, Lung cancer Oncologist and Researcher at IEO, recently shared on X: "Just out…
Apr 22, 2024, 19:23 | Insight
New Paper Alert! A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners Foundation
A Comprehensive Review of ADCs in Lung and Breast Cancer by the ETOP IBCSG Partners…
Apr 15, 2024, 17:01 | Drugs
Elisa Agostinetto: It’s likely that adjuvant Pembrolizumab has a lower impact compared to neoadjuvant Pembrolizumab
Elisa Agostinetto, Research Physician at the Institute of Jules Bordet in Brussels, posted on X/Twitter:…
Apr 12, 2024, 09:26 | Insight
In this Letter to the Editor, the Cancer Immunotherapy AEs Working Group details the pitfalls of reporting in immunotherapy clinical trials - Annals of Oncology
Annals of Oncology shared a post on X: "Immune checkpoint inhibitors are now standard-of -care in…
Mar 17, 2024, 19:51 | Insight
Tom Powles: New ESMO's guidlines for advanced bladder cancer Annals of Oncology - Enforumab Vedotin and pembrolizumab is the new standard of care
Tom Powles, Director of Barts Cancer Center, shared a post on X: "New ESMO's guidelines for…
Mar 15, 2024, 15:26 | Insight
Enfortumab+pembrolizumab combination as the 1st line treatment of choice for advanced urothelial cancer - summary by Piotr J. Wysocki
Piotr J. Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital,…
Feb 28, 2024, 12:34 | Blog
Erman Akkus: Early onset colorectal cancer, 2 recent studies
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "Early onset colorectal cancer…
Feb 21, 2024, 18:13 | Insight
Erman Akkus: Tremelimumab plus durvalumab (STRIDE) in HCC-HIMALAYA update
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "Tremelimumab plus durvalumab (STRIDE)…
Feb 10, 2024, 15:34 | Insight
Alessandro Russo: Our editorial on the potential role of ctDNA in resectable NSCLC undergoing neo-adj chemo
Alessandro Russo, Medical Oncologist at A.O. Papardo, Messina, recently shared the following insight on X/Twitter:…
Jan 4, 2024, 16:59 | Insight
Vinay Prasad: When do the checkpoint inhibitors work
Vinay Prasad, Professor in the Department of Epidemiology and Biostatistics at the University of California…
Jan 3, 2024, 20:43 | Opinion
Erman Akkus: Future biomarkers will be more than PD-L1 for ICI
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: “B-cell infiltration as a…
Dec 31, 2023, 06:06 | Blog
David Gandara: “not so fast”
David Gandara, Director of Thoracic Oncology and Senior Advisor to the Director at University of…
Dec 15, 2023, 15:59 | Insight,Opinion
Vivek Subbiah: Precision Medicine for FGFR in bladder cancer has now arrived
Vivek Subbiah shared on X/Twitter: “Just published Annals of Oncology. Pleased to share our editorial "Unlocking…
Nov 21, 2023, 13:57 | Blog
Vivek Subbiah: Honored to co-author with brilliant "Guru" of bladder cancer Guru Sonpavde.
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…
Sep 7, 2023, 22:03 | Insight
Arndt Vogel: We provide comprehensive recommendations for PDAC.
Arndt Vogel, Managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology…
Aug 23, 2023, 23:49 | Blog
Paolo Tarantino: Interesting pan-cancer evaluation of HER2-low expression out on Annals of Oncology.
Paolo Tarantino, a Research Fellow at the Dana-Farber Cancer Institute, shared the following insights on…
All: 100 Posts: 1 - 100
Special Coverage